ãŠã€ã«ã¹ãåãåºãããåŽã®ãããã³ã«ãã¹ã¯ãè£
çãããŠSARS-CoV-2ã空éäžã«åŽåºããããšããã¹ã¯ã®è£
çã«ãããŠã€ã«ã¹ã®åžã蟌ã¿éã倧ããäœäžããããšãæãããšãªããŸããã
ãã®ããšã¯ãã¹ã¯ã«ã¯ãŠã€ã«ã¹ã®åžã蟌ã¿ãæããåãããã察é¢ãã人ãžã®æŽé²éãæžããå¹æãé«ãããšã瀺åããŠããŸããããã«ããŠã€ã«ã¹ãåãåºãåŽã®ãããã³ã«åžãã¹ã¯ãŸãã¯å€ç§çšãã¹ã¯ãè£ çãããåžã蟌ãåŽã®ãããã³ã«åçš®ã®ãã¹ã¯ãè£ çããããšçžä¹çã«ãŠã€ã«ã¹ã®åžã蟌ã¿éãæžå°ããããšãããããŸããã
äžè¿°ã®å®éšã§ã¯å®éæ§ã確ä¿ããããã«é«æ¿åºŠã®ãŠã€ã«ã¹ãåŽé§ããŠè§£æãè¡ããŸããã
COVID-19ææè ã®åŒæ°ã«å«ãŸãããŠã€ã«ã¹éãäžæã§ãããããåŽé§ãããŠã€ã«ã¹éã段éçã«æžãããå®éšãè¡ã£ããšãããåžãã¹ã¯ãå€ç§çšãã¹ã¯ãªãã³ã«N95ãã¹ã¯ççšæã«ãããŠãã¹ã¯ãééããæææ§ãŠã€ã«ã¹ã¯ããããæ€åºéçæªæºã§ããã
ãã®ããšã¯ãã¹ã¯ã«ã¯ãŠã€ã«ã¹ã®åžã蟌ã¿ãæããåãããã察é¢ãã人ãžã®æŽé²éãæžããå¹æãé«ãããšã瀺åããŠããŸããããã«ããŠã€ã«ã¹ãåãåºãåŽã®ãããã³ã«åžãã¹ã¯ãŸãã¯å€ç§çšãã¹ã¯ãè£ çãããåžã蟌ãåŽã®ãããã³ã«åçš®ã®ãã¹ã¯ãè£ çããããšçžä¹çã«ãŠã€ã«ã¹ã®åžã蟌ã¿éãæžå°ããããšãããããŸããã
äžè¿°ã®å®éšã§ã¯å®éæ§ã確ä¿ããããã«é«æ¿åºŠã®ãŠã€ã«ã¹ãåŽé§ããŠè§£æãè¡ããŸããã
COVID-19ææè ã®åŒæ°ã«å«ãŸãããŠã€ã«ã¹éãäžæã§ãããããåŽé§ãããŠã€ã«ã¹éã段éçã«æžãããå®éšãè¡ã£ããšãããåžãã¹ã¯ãå€ç§çšãã¹ã¯ãªãã³ã«N95ãã¹ã¯ççšæã«ãããŠãã¹ã¯ãééããæææ§ãŠã€ã«ã¹ã¯ããããæ€åºéçæªæºã§ããã